Literature DB >> 3487242

Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries.

L A Simons.   

Abstract

Coronary risk factors differ in importance from country to country, but a proportion of interpopulation differences in coronary artery disease (CAD) mortality is probably closely related to interpopulation differences in total serum cholesterol levels. Interpopulation differences in high density lipoprotein (HDL) cholesterol levels supposedly do not explain interpopulation differences in CAD mortality, although HDL cholesterol may be an important negative risk factor within a population. Age- and sex-specific serum cholesterol, triglyceride and HDL cholesterol levels have been sought for 27 industrialized countries for which the World Health Organization has reliable mortality data. At least partially complete information was obtained from 19 countries, derived from national or regional studies in middle-aged subjects, and this has been related to CAD mortality rates. In men, 45% of the interpopulation variation in CAD mortality was explained by variation in serum cholesterol levels; 32% by variation in HDL cholesterol; and 55% by variation in the ratio of total serum cholesterol/HDL cholesterol. CAD mortality in men did not correlate with a population's serum triglyceride levels. In women, the only significant correlate of interpopulation variation in CAD mortality was the ratio of total serum cholesterol/HDL cholesterol, which explained 31% of the variation in CAD mortality. These findings highlight the contributions of total serum cholesterol and the ratio of total serum cholesterol/HDL cholesterol to CAD mortality in men at the international level and have implications for individual members of a population. Similar analyses in women were not particularly informative.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3487242     DOI: 10.1016/0002-9149(86)90659-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  21 in total

Review 1.  Squalene synthase inhibitors.

Authors:  V C Menys; P N Durrington
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

2.  Effects of Ava II and Hinc II polymorphisms at the LDL receptor gene on serum lipid levels of Brazilian individuals with high risk for coronary heart disease.

Authors:  L A Salazar; M H Hirata; S D Giannini; N Forti; J Diament; J S Issa; R D Hirata
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

Review 3.  Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.

Authors:  Valentine Charlton-Menys; Paul N Durrington
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Profile of an ideal antianginal agent.

Authors:  E J Lazar; W H Frishman
Journal:  Drugs       Date:  1989       Impact factor: 9.546

Review 5.  The independent roles of diet and serum lipids in the 20th-century rise and decline of coronary heart disease mortality.

Authors:  R H Rosenman
Journal:  Integr Physiol Behav Sci       Date:  1993 Jan-Mar

Review 6.  The effect of exercise on lipid metabolism in men and women.

Authors:  L Goldberg; D L Elliot
Journal:  Sports Med       Date:  1987 Sep-Oct       Impact factor: 11.136

7.  The acute effect of marathon running on plasma lipoproteins in female subjects.

Authors:  E R Skinner; C Watt; R J Maughan
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1987

8.  Elevated high-density-lipoprotein cholesterol and normal triglycerides as markers of longevity.

Authors:  M Nikkilä; T Pitkäjärvi; T Koivula; J Heikkinen
Journal:  Klin Wochenschr       Date:  1991-10-31

Review 9.  Cholesterol and coronary disease--outstanding questions.

Authors:  M F Oliver
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

10.  Relevance of cholesterol screening in the United Arab Emirates. A preliminary study.

Authors:  M M Agarwal; P F Hughes; A A Haliga; P Newman; M M Sheekh-Hussen; A G Shalabi
Journal:  Eur J Epidemiol       Date:  1995-10       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.